Papers by M Grundman · AgingResearch.News

AAIC 2025 Abstract9 Jan
Plasma proteomic analysis of a biomarker‐defined subpopulation in the SHINE Ph2 trial to identify molecular correlates to the favorable decrease in the neuroinflammatory marker GFAP with zervimesine in Alzheimer's disease participants
Trial in peopleInterventions
Paper
AAIC 2025 Abstract26 Dec
Baseline Characteristics and Results of the Phase 2 COG1201 SHIMMER Study of Zervimesine (CT1812)
Trial in peopleInterventions
Paper
AAIC 2025 Abstract26 Dec
Zervimesine (CT1812) Treatment Benefits Patients with Lower Baseline Plasma p‐tau217 Across the Mild‐to‐Moderate AD Spectrum
Trial in peopleInterventions
Paper
AAIC 2025 Abstract26 Dec
Exploratory CSF proteomic analysis of a pre‐specified pTau217 subgroup from the SHINE clinical trial identifies biomarkers correlated with cognitive improvement in Alzheimer’s disease patients treated with zervimesine
Trial in peopleInterventions
Paper

AAIC 2025 Abstract25 Dec
Low‐Dose Interleukin‐2 in Patients with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial
Trial in peopleInterventions
Paper